GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » Gross Margin %

Item 9 Labs (Item 9 Labs) Gross Margin % : 56.13% (As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Item 9 Labs's Gross Profit for the three months ended in Jun. 2023 was $2.82 Mil. Item 9 Labs's Revenue for the three months ended in Jun. 2023 was $5.02 Mil. Therefore, Item 9 Labs's Gross Margin % for the quarter that ended in Jun. 2023 was 56.13%.

Warning Sign:

Item 9 Labs Corp gross margin has been in long-term decline. The average rate of decline per year is -6.5%.


The historical rank and industry rank for Item 9 Labs's Gross Margin % or its related term are showing as below:

INLB' s Gross Margin % Range Over the Past 10 Years
Min: -3.54   Med: 39.92   Max: 66.8
Current: 49.8


During the past 13 years, the highest Gross Margin % of Item 9 Labs was 66.80%. The lowest was -3.54%. And the median was 39.92%.

INLB's Gross Margin % is ranked better than
56.46% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.705 vs INLB: 49.80

Item 9 Labs had a gross margin of 56.13% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Item 9 Labs was -6.50% per year.


Item 9 Labs Gross Margin % Historical Data

The historical data trend for Item 9 Labs's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs Gross Margin % Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.96 48.20 40.58 39.26 33.61

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.24 16.15 52.40 65.65 56.13

Competitive Comparison of Item 9 Labs's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Gross Margin % falls into.



Item 9 Labs Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Item 9 Labs's Gross Margin for the fiscal year that ended in Sep. 2022 is calculated as

Gross Margin % (A: Sep. 2022 )=Gross Profit (A: Sep. 2022 ) / Revenue (A: Sep. 2022 )
=7.3 / 21.757
=(Revenue - Cost of Goods Sold) / Revenue
=(21.757 - 14.445) / 21.757
=33.61 %

Item 9 Labs's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=2.8 / 5.022
=(Revenue - Cost of Goods Sold) / Revenue
=(5.022 - 2.203) / 5.022
=56.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Item 9 Labs  (OTCPK:INLB) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Item 9 Labs had a gross margin of 56.13% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Item 9 Labs Gross Margin % Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Item 9 Labs (Item 9 Labs) Business Description

Traded in Other Exchanges
N/A
Address
2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Executives
Taylor Lawrence X. Iii director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey director C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden director C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven officer: Chief Operating Officer 5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson director, officer: Chief Executive Officer 1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden director 3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen officer: CFO, Secretary, Treasurer 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan 10 percent owner 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier 10 percent owner 1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla director, officer: President 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md director, officer: President 10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership director, officer: President & CEO 10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith officer: CFO, Secretary, Treasurer 8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson officer: Chief Operating Officer 8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251